Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
Molecular Cancer Therapeutics|October 24, 2013
Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testingDror Alishekevitz, Rotem Bril, David Loven, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2009
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial mannerLiat Izhak, Gizi Wildbaum, Uri Weinberg, et al.
Biomaterials|February 26, 2013
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastasesKeren Miller, Chiara Clementi, Dina Polyak, et al.
Oncogene|January 9, 2004
Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomeraseBrian J Pak, Jane Lee, Boun L Thai, et al.
Cancers|August 30, 2020
The Potential Role of Immune Alteration in the Cancer-COVID19 Equation-A Prospective Longitudinal StudyTal Goshen-Lago, Moran Szwarcwort-Cohen, Madeleine Benguigui, et al.
Scientific Reports|September 1, 2019
Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cellsMadeleine Benguigui, Iris S Weitz, Michael Timaner, et al.
Molecular Cancer Therapeutics|October 15, 2009
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft modelsLaura G Daenen, Yuval Shaked, Shan Man, et al.
Cancer Research|August 17, 2005
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategyYuval Shaked, Urban Emmenegger, Giulio Francia, et al.
The Journal of Pathology|April 3, 2016
Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacyOfrat Beyar-Katz, Ksenia Magidey, Neta Ben-Tsedek, et al.
Current Cancer Drug Targets|November 25, 2005
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic doseYuval Shaked, Guido Bocci, Raquel Munoz, et al.
Pageof 14